Trial Profile

A Phase 1 Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Ovarian and Cervical Carcinoma, Sarcomas, and Neuroendocrine Tumors Including Small Cell Lung Cancer and Merkel Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Topotecan (Primary)
Indications Carcinoma; Merkel cell carcinoma; Ovarian cancer; Solid tumours; Uterine cancer
Focus Adverse reactions; First in man
Sponsors FujiFilm Pharmaceuticals USA

24 Jul 2024 Planned primary completion date changed from 1 Mar 2025 to 1 Dec 2025.
24 Apr 2024 Protocol is amended to remove Cohort E2: advanced cervical cancer, Cohort E3: advanced sarcomas, Cohort E4: advanced neuroendocrine tumors including small cell lung cancer.
24 Apr 2024 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com